The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Huperzine A is a compound sold over the counter at least in the United States that can increase acetylcholine transmission, a different neuromodulator entirely. But what's interesting is that huperzine A somehow by way of interactions between the cholinergic system and the dopaminergic system leads to increases in dopamine in the medial prefrontal cortex and hippocampus.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And so I think the reason why we're seeing an increase in popularity of companies including huperzine A and nootropic compounds is both for the cholinergic stimulating properties, but also for stimulating dopamine release. I personally have never tried huperzine A.